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Abstract.
Background: Mitochondrial disease can present at any age, with dysfunction in almost any tissue making diagnosis a challenge.
It can result from inherited or sporadic mutations in either the mitochondrial or the nuclear genome, many of which affect
intraorganellar gene expression. The estimated prevalence of 1/4300 indicates these to be amongst the commonest inherited
neuromuscular disorders, emphasising the importance of recognition of the diagnostic clinical features.
Objective: Despite major advances in our understanding of the molecular basis of mitochondrial diseases, accurate and early
diagnoses are critically dependent on the fastidious clinical and biochemical characterisation of patients. Here we describe a
patient harbouring a previously reported homozygous mutation in C12orf65, a mitochondrial protein of unknown function,
which does not adhere to the proposed distinct genotype-phenotype relationship.
Methods: We performed clinical, biochemical and molecular analysis including whole exome sequencing on patient samples
and cell lines.
Results: We report an extremely rare case of an adult presenting with Leigh-like disease, in intensive care, in the 5th decade
of life, harbouring a recessively inherited mutation previously reported in children. A global reduction in intra-mitochondrial
protein synthesis was observed despite normal or elevated levels of mt-RNA, leading to an isolated complex IV deficiency.
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Conclusions: All the reported C12orf65 mutations have shown an autosomal recessive pattern of inheritance. Mitochondrial
disease causing mutations inherited in this manner are usually of early onset and associated with a severe, often fatal clinical
phenotype. Presentations in adulthood are usually less severe. This patient’s late adulthood presentation is in sharp contrast
emphasising the clinical variability that is characteristic of mitochondrial disease and illustrates why making a definitive diagnosis
remains a formidable challenge.
Keywords: Mitochondria, respiratory insufficiency, schizophrenia, human C12orf65 protein, protein biosynthesis, peptide
termination factors
ABBREVIATIONS
Mt Mitochondrial
COX Cytochrome c oxidase, CIV
H&E Hematoxylin and eosin
MRI Magnetic resonance imaging
MRS Magnetic resonance spectroscopy
BN-PAGE Blue native polyacrylamide gel
electrophoresis
RC Respiratory chain
OXPHOS Oxidative phosphorylation
LONP Mitochondrial Lon Protease Homolog
CLPX Caseinolytic Mitochondrial Matrix
Peptidase Chaperone Subunit.
INTRODUCTION
The mitochondrial genome (mtDNA) encodes 13
open reading frames in addition to the tRNAs and
rRNAs required for intramitochondrial protein synthe-
sis [1]. The remaining components that comprise or
facilitate assemble the mitoribosome are encoded by
the nucleus. Mutations in any of these genes that affect
expression of mtDNA can potentially cause mito-
chondrial (mt) disease [2–5], a heterogeneous group
of disorders characterized by compromised oxida-
tive phosphorylation. The application of whole exome
sequencing to patients with well-characterised mito-
chondrial disease has revealed new nuclear disease
genes to be correlated with pathways where their
involvement had not previously been known, or had
been predicted but not confirmed [6]. The C12orf65
gene falls into the latter category; it is a member of the
mitochondrial release factor [7] family, some but not
all members of which have been shown to cleave the
terminal tRNA from the nascent peptide in the mitori-
bosome, allowing the newly made protein to escape
the translation machinery.
Despite its predicted role in mt-translation, this
was not confirmed until the first report of a patient
presenting with a pathogenic mutation in C12orf65
[OMIM 613541] leading to decreased mt-protein
synthesis [8]. Subsequently a number of patients
with C12orf65 mutations have been reported pre-
senting with similar symptoms of mitochondrial
disease [8–14] (Table 1). The predicted conse-
quence of the mutations is that truncated versions
of C12orf65 protein would be synthesised, where
the length of the protein depended on the precise
position of the stop codon. A clinical review of
patients with C12orf65 mutations has proposed that
distinct genotype-phenotype relationships can be dis-
tinguished in this patient group, despite the broad
spectrum of symptoms [9]. These authors suggest that
although the degree of protein truncation dictates the
severity, an ‘obligatory clinical triad’ of optic atro-
phy, peripheral neuropathy and spastic paraparesis is
characteristic for all patients.
Table 1
Summary of clinical features reported in previously reported
patients∗ harbouring pathogenic mutations in C12orf65
Clinical Symptoms Reference
Optic atrophy† [8, 9, 11–14, 32]
Pyramidal signs† [9, 10, 12, 13, 32]
Intellectual disability [8–10, 12–14]
Neuropathy (including distal weakness, foot
deformity†)
[8, 9, 11–14]
Ophthalmoparesis [8, 10, 13, 32]
Facial muscle weakness [8, 13, 32]
Cerebellar involvement (intentional tremor,
dysmetria, ataxia)
[8, 13, 32]
MRI changes consistent with Leigh
syndrome
[8, 13, 32]
Dysmorphic facies (hypertelorism, broad
nasal bridge)
[10, 13]
Bulbar involvement [8, 32]
Respiratory compromise/failure [8, 32]
Macular colloid bodies [12]
Retinitis pigmentosa [12]
Cardiomyopathy [32]
Arthrogryposis [10]
Scoliosis [12]
Paralytic ileus [8]
Urinary stress incontinence [8]
Ovarian failure [14]
∗Previously reported patients (n = 27), †Clinical triad symptom.
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Here, we describe a late presentation of LS and
respiratory failure in a patient with long stand-
ing schizoaffective disorder, harbouring a previously
reported C12orf65 mutation where the severity of the
clinical presentation does not correlate with the length
of the truncated C12orf65 protein. This mutation pre-
dicts one of the shortest aberrant C12orf65 proteins,
and although the symptoms of the minimal obligatory
triad were present, the patient only presented to the
intensive care unit as an adult in the 5th decade of life.
We have characterised respiratory capacity in skeletal
muscle and fibroblasts, assessed de novo mitochon-
drial translation in patient fibroblasts and interrogated
the steady state levels of respiratory chain proteins,
confirming an isolated mitochondrial complex IV defi-
ciency.
All the reported C12orf65 mutations have shown
an autosomal recessive pattern of inheritance. Mito-
chondrial disease causing mutations inherited in this
manner are usually of early onset and associated with
a severe, often fatal clinical phenotype. The case pre-
sented here is in contrast to this pattern emphasising
the importance of recognising the breadth of diagnos-
tic clinical features, especially in light of the estimated
prevalence of 1:4300, which indicates that these are
amongst the most common inherited neuromuscular
disorders [5].
MATERIALS AND METHODS
Case report
The male patient was a term birth, to healthy, non-
consanguineous parents, and reached developmental
milestones appropriately. At 2 years he underwent a
surgical procedure for hypospadias and experienced
perioperative respiratory arrest. He was felt to have
suffered mild hypoxic brain damage, as evidenced by
mild dysarthria, mild fixed limb spasticity and cog-
nitive developmental delay but progressed through
normal schooling and remained independent. No bul-
bar dysfunction or regression was ever documented.
He underwent a tendon lengthening procedure at age
14 years with no untoward sequelae. He was diag-
nosed with schizoaffective disorder in his second
decade of life requiring multiple hospital admissions
but remained relatively asymptomatic in his later
years.
In his fifth decade of life, six months prior to
his acute admission, he was noted to have deteri-
orated physically reporting shortness of breath on
exertion and worsening mobility requiring two sticks
to mobilise with the need for a wheelchair for longer
distances. His dysarthria had also progressively wors-
ened.
At 45-years-old this man presented to his acute care
hospital following a fall at home. On admission he was
noted to be drowsy, with a reduced Glasgow coma scale
of 13 out of 15, low grade pyrexia of 38◦C, tachyp-
noea (respiratory rate 21), tachycardia (100 bpm) and
hypoxic (69% on room air). An arterial blood gas
showed a pH of 7.20, pCO2 14.7kPa, pO2 9.3kPa
and bicarbonate of 37.8 mmol/L consistent with type
II respiratory failure. A chest X-ray showed patchy
consolidation of the left base, white cell count was
12.2 and CRP less than 1. He was initially commenced
on non-invasive ventilation but continued rapid dete-
rioration warranted assisted ventilation. CT head was
normal. On transfer to critical care he was treated for
a presumed pneumonia, he responded well and was
extubated after 48 hours, requiring intermittent non-
invasive ventilation only for elevated pCO2. He then
developed massive hematemesis and rapidly became
haemodynamically unstable (systolic BP 90 mm Hg,
pulse rate; 130 bpm) necessitating transfusion. He
required urgent laparotomy and repair of a perforated
duodenal ulcer but following the anaesthetic had a pro-
tracted hospital stay. He remained ventilator dependent
via a tracheostomy related to gross disturbance of cen-
tral respiratory drive compounded by diaphragmatic
weakness and respiratory muscle weakness. Bulbar
function remained profoundly poor, necessitating the
placement of a percutaneous endoscopic gastrostomy
feeding tube.
Histochemical and biochemical analyses
Standard histological (H&E) and histochemical
(COX/SDH) analyses of skeletal muscle biopsies were
performed on fresh-frozen skeletal muscle sections
(10m) [15]. Mitochondrial respiratory chain com-
plex activities were determined in skeletal muscle
and fibroblast homogenates and expressed relative
to the activity of the matrix marker enzyme, citrate
synthase [16].
Molecular genetics
Total DNA was extracted from muscle; mtDNA rear-
rangements investigated by long-range PCR [17] and
direct sequencing of the entire mtDNA genome was
undertaken as previously described [18]. Alignment
and variant calling were performed using SeqScape
software v2.6 (Life Technologies, Warrington, UK)
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using the revised Cambridge reference sequence for
human mtDNA (GenBank accession: NC 012920.1)
[19]. Whole exome sequencing and bioinformatics
was performed as previously described [13]. Briefly,
genomic DNA was fragmented and enriched by Illu-
mina TruSeq™ 62Mb exome capture and sequenced
(Illumina HiSeq 2000, 100 bp paired-end reads). Bioin-
formatics pipeline included alignment to the human
reference genome (UCSC hg19) and variant detec-
tion (Varscan v2.2, Dindel v1.01) [20]. On-target
variant filtering excluded minor allele frequencies
(greater >0.01) in several databases and 343 unrelated
in-house controls as previously shown. ANNOVAR
was used to define homozygous/compound heterozy-
gous variants and protein altering and/or putative
‘disease causing’ mutations [21]. Candidate genes
were ranked by previous association with disease
phenotypes [22]. The C12orf65 variant was con-
firmed by Sanger sequencing (primers; Forward
5′-TCATCTAACCCAGGTCCTCAG-3′; Reverse 5′-
AGGCTGTGGAACCCTTGG-3′; GenBank acces-
sion: NM 152269.4) [18].
Cell culture
Cells were routinely cultured [23] in DMEM sup-
plemented with 10% FCS, 2 mM L-glutamine, 1x
NEAA, 1 mM pyruvate, 50g/ml uridine, with either
4500 mg/L glucose or 10 mM galactose, at 37◦C, in
a humidified 5% CO2 atmosphere. Transfection of
HEK293 cells with siRNAs was performed with 30nM
final concentration as previously described [7]. Control
non-targetting (NT) and custom synthesised against
C12orf65 (sense 5′-GGG AGA AGC UGA CGU UGU
U dTdT) siRNAs were from Eurogentec.
BN-PAGE, SDS-PAGE and western blotting
For BN PAGE, mitochondrial lysates solubilised
with dodecylmaltoside (3.2 g/g protein) from patient
and control fibroblasts (25g per lane) were separated
on 4.5–16% gels as described in [24]. For SDS-PAGE,
mitochondrial lysates were prepared from patient and
control fibroblasts and 12.5g per lane separated on
12% gels as described in [23].
Proteins were transferred to PVDF membranes (GE
Healthcare) for immunoblotting. Primary antibodies
used were; Complex I - NDUFB8, NDUFA9; Complex
II - SDHA (70 kDa flavoprotein subunit); Complex III
- UQCRC2 (Core 2); Complex IV - COX4, COX2;
Porin; MRPL3, CLPX, Complex V (-subunit) (all
Abcam). ICT1, MRPS26, MRPS27, MRPL45 (PTG
Labs); HSP60 (BD Biosciences); LonP (Sigma Life
Science). Appropriate HRP-conjugated immunoglob-
ulin secondary antibodies (Dako, Glostrup, Denmark)
were used and detected with ECL-Prime (GE Health-
care) as per the manufacturer’s instructions.
Metabolic labelling of mitochondrially encoded
proteins
This was essentially as described in Chomyn [25].
Patient and control fibroblasts were metabolically
labelled ([35S]-methionine/cysteine) for 1 hour with
emetine inhibition of cytosolic translation. Total cell
lysates (50g) were separated by 15% SDS-PAGE.
Signals from newly synthesised mt-proteins were
detected from dried gels via PhosphoImaging and
ImageQuant software (GE Healthcare). Gels were
Coomassie blue stained to confirm equal loading.
Northern analysis
Total RNA from control and patient fibroblasts
or HEK293 cells was extracted using Trizol (Life
Technologies). Aliquots (4g) were electrophoresed
through 1.2% denaturing agarose, and transferred to
Genescreen Plus. Probes were generated using random
hexamers on PCR generated templates corresponding
to the internal regions of the genes of interest, as pre-
viously described [26].
RESULTS
Clinical findings
Neurophysiological evaluation was consistent with
an axonal neuropathy. On examination the patient had
bilateral ptosis, horizontal gaze paresis and bilateral
optic atrophy. He had mild facial muscle weakness,
palatal myoclonus, a reduced gag reflex and dysarthria.
There was severe distal muscle wasting of upper and
lower limbs. Upper and lower limb reflexes were
pathologically brisk, with the exception of ankle and
plantar reflexes, which were absent. Initial neuropathy
screen including serum protein electrophoresis, cop-
per, caeruloplasmin, acylcarnitines, carnitine, phytanic
acid, very long chain fatty acids, -fetoprotein and uri-
nary organic acids were normal. Serum lactate was
3.7 mmol/L (normal range <2.0 mmol/l).
MRI of the head showed extensive swelling and
abnormal high T2-weighted signal changes centrally
within the medulla and dorsal pons. Additional small
foci of restricted diffusion were seen within the
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Fig. 1. MRI revealed abnormalities consistent with mitochondrial disease. Cranial MRI was performed showing swelling and abnormal high
T2-weighted signal changes centrally within the dorsal pons (A, red arrow) and medulla (B, C red arrows). Other small foci of restricted diffusion
were detected and also seen within the cerebellar hemispheres (A, yellow arrow).
brainstem and the cerebellar hemispheres (Fig. 1).
Brain MRS showed a lactate peak, with reduced NAA
and raised choline in a voxel centred over the brain
stem. Combined these radiological findings were con-
sistent with a diagnosis of Leigh syndrome.
Characterisation of respiratory capacity
in skeletal muscle and fibroblasts
A diagnostic muscle biopsy was performed to
formally investigate a likely mitochondrial disor-
der. Although the muscle appeared morphologi-
cally normal, histochemical analysis of oxidative
enzymes including succinate dehydrogenase (SDH)
and cytochrome c oxidase (COX) revealed a gener-
alised decrease in COX activity throughout the biopsy
sample, confirmed by the sequential COX-SDH assay
(Fig. 2A). Spectrophotometric assays of mitochondrial
respiratory chain enzyme activities revealed a severe
(approximately 20% of control values) and isolated
COX (CIV) deficiency in the muscle of our patient
(Fig. 2B). The identical biochemical defect was also
observed, to a lesser degree, in the patient’s cultured
fibroblasts (approximately 50% of control) (Fig. 2C).
The activities of all other RC complexes were normal,
confirming an isolated CIV deficiency.
Cell morphology (Fig. 2D) and growth rate of
fibroblasts derived from the patient were compa-
rable to control cells on glucose. However, these
failed to proliferate on galactose (Fig. 2E, F), a
substrate that forces cells to utilise oxidative phos-
phorylation rather than glycolysis for ATP production.
This observation confirmed that the cells express
a mitochondrial respiratory chain defect, consistent
with the decrease in complex IV activity determined
spectrophotometrically.
Identification of pathogenic C12orf65 mutation
Diagnostic molecular genetic studies excluded
mtDNA depletion, mtDNA rearrangements and
mtDNA point mutations as a cause of the respira-
tory chain defect in muscle. Whole exome capture and
sequencing identified a homozygous exonic deletion
(c.210delA, p.(Gly72Alafs∗13) frameshift mutation
(Fig. 3A), predicted to encode a truncated version of
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the protein due to the introduction of a premature stop
codon (Fig. 3B). This was identical to the mutation
described in the first report of C12orf65 patients [8].
Subsequent C12orf65 reports also identified truncat-
ing mutations [8–13]. Although premature stop codons
often trigger non-sense mediated decay (NMD) to
degrade transcripts and so prevent synthesis of aberrant
polypeptides, control levels of C12orf65 mRNA were
reported ([8, 12], and data not shown) and one study
detected a truncated C12orf65 protein [11] suggesting
that aberrant C12orf65 transcripts identified thus far
escape normal NMD.
As with our patient’s mutation, a number of the
reported mutations predict not only a truncated protein
but also the loss of the highly conserved GGQ motif,
a determining feature of release factors. This criti-
cal feature is essential for triggering peptidyl-tRNA
hydrolysis, which cleaves the ester bond between the
P-site tRNA and the nascent polypeptide chain [27, 28].
Since loss of this motif or the whole protein may affect
synthesis of all mitochondrially encoded polypeptides,
intraorganellar translation was analysed by metabolic
labelling.
C12orf65 mutation disrupts expression of
respiratory complexes
De novo mitochondrial translation was assessed in
patient fibroblasts and indicated a global decrease
in protein synthesis (Fig. 4A), as seen in previously
reported patients. This reduction in mt-protein synthe-
sis is not a consequence of a reduction in mt-RNA
levels, which are modestly elevated (Fig. 4B), again as
seen in other C12orf65 patients. When cells are artifi-
cially depleted of C12orf65 protein using siRNA, the
elevation in mt-RNA levels is more striking (Fig. 4C).
A mitoribosome defect is unlikely to be responsible in
this patient, as no global differences were observed in
the steady state levels of mitoribosomal protein levels
(Fig. 4D).
To identify if the synthesised polypeptides are
stable, steady state levels of RC proteins were
assessed by western blotting following SDS-PAGE.
This confirmed decreased levels of complex IV
(COX2 expression), consistent with our biochemi-
cal assays but also revealed reduced levels of CI
and modest changes in CIII subunits (Fig. 4E). To
determine if synthesised polypeptides were incorpo-
rated into fully assembled oxidative phosphorylation
complexes, western blots of mitochondrial fractions
separated by 1D BN-PAGE were performed. A reduc-
tion in the amount of fully assembled complexes
I, IV and V was observed in the patient com-
pared to controls, together with a minor complex III
defect, visible in the I+III supercomplex (Fig. 4F).
These data are consistent with C12orf65 playing a
ubiquitous role in mt-translation but with a more
severe effect on CIV activity. This translation defect
caused by loss of C12orf65 does not appear to trig-
ger an unfolded protein response as no increase
was seen in relevant proteases (Fig. 4G, LONP and
CLPX).
DISCUSSION
Here we present the comprehensive clinical, genetic,
biochemical, and molecular characterisation of an
adult patient harbouring a mutation in the C12orf65
gene. Although 27 patients with recessively inher-
ited C12orf65 mutations have been documented in the
literature (Table 1), this individual had an atypical pre-
sentation, highlighting how different the aspects of
their clinical and/ or molecular features can be.
The precise role of C12orf65 has not yet been fully
elucidated, however, studies depleting cells of this
protein together with analysis of patient cell lines car-
rying mutations clearly indicates a role in mt-protein
synthesis. This is consistent with the evolutionary
conservation of the GGQ domain that determines its
ribosome dependency and designation as a translation
release factor [7]. Deleterious mutations that disrupt
the GGQ motif are predicted to result in a more severe
phenotype, whereas downstream C-terminal mutations
have been reported with more favourable phenotypic
presentations that typically lack cognitive impairment
[9]. The patient described herein, harbours a mutation
in the C12orf65 gene that would, therefore, predict
both a severe and early-onset presentation. This pre-
diction is reinforced by the same mutation having
←−————————————————————————————————————————————
Fig. 2. Histochemical, biochemical and cellular analyses indicate mitochondrial dysfunction. A. Serial cryosections of the patient’s muscle biopsy
(upper panels) were assessed histologically (H&E) and histochemically for oxidative enzyme activities including succinate dehydrogenase (SDH)
and cytochrome c oxidase (COX) and the sequential COX-SDH reaction and compared to controls (lower panels). Respiratory chain complex
activities were determined spectrophotometrically in skeletal muscle (B) and fibroblast (C) homogenates and presented as a % of control values.
Morphology (D) and growth of patient and control fibroblasts was monitored over 6 days in glucose (E) and galactose (F) n = 3 experimental
repeats. Representative differences in density and morphology of the patient and control fibroblasts after 6 days in galactose are presented (D).
Scale bar = 50m.
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Fig. 3. Sanger sequence analysis of C12orf65 patient gene. A. Region of an electropherogram of Sanger sequencing of the C12orf65 gene from
the patient (upper panel) and wildtype control (lower panel), aligned to the GenBank accession: NM 152269.4 [19]. The green arrow indicates
the position of the adenine nucleotide in control sample that is deleted from the patient’s genome. B. Schematic demonstrating the consequence
of the single nucleotide deletion on the peptide sequence. The resultant frameshift introduces amino acid changes and a premature UGA stop
codon (grey box) predicted to encode a truncated protein. The alterations to the functional conserved GGQ motif are also boxed in grey.
originally been reported in children with impairment
of mitochondrial translation and severe decreases in
activities of complexes I, IV and V [8]. In distinction
to these expectations this patient presented in adult-
hood (aged 45 years) with milder symptoms and an
isolated complex IV defect. Although the ‘obligatory
clinical triad’ of symptoms was present there were
other distinctive features in this patient’s presentation.
The patient suffered from shortness of breath and
associated respiratory muscle weakness, consistent
with a long term deficiency in respiratory chain (RC)
enzyme activities. To date, only 3 published cases of
C12orf65-related mitochondrial disease have reported
respiratory failure; but age of onset varies from 4 to
14 years. This unusual cause of failure to wean from a
respirator in a man in his fifth decade of life was, there-
fore, likely precipitated by a marked catabolic state,
resulting from compromised respiratory chain activ-
ity. Spectrophotometric analysis of respiratory chain
complexes indicated a severe and isolated complex
IV deficiency, consistent with the growth defect seen
in patient fibroblasts when challenged to respire on
galactose. Intriguingly however, our molecular inves-
tigations of individual mt-RNA species, proteins and
OXPHOS complex formation revealed a complex reg-
ulation of gene expression. Elevation of the mt-mRNAs
encoding OXPHOS components did not correlate with
elevated protein levels, nor did modest decreases in
protein levels of specific complex I and V components
compromise complex activities. Indeed, biochemically
we were able to find only an isolated complex IV
deficiency. This lack of complex I dysfunction also
marked this phenotype as different from the biochem-
ical defects reported in published cases.
Of the mitochondrial disease patients for whom
there is no current molecular diagnosis, approximately
30% exhibit defects in mitochondrial translation [6].
Incorporating whole exome sequencing into diagnostic
algorithms is facilitating molecular genetic diagnoses
but it is clear that identifying a pathogenic mutation in a
gene encoding a relevant mitochondrial protein is only
the first step towards understanding the molecular basis
of mitochondrial disease. For example, mitochondrial
aminoacyl tRNA synthetases (mt-aaRS) are responsi-
ble for adding the appropriate amino acid to the cognate
mt-tRNA. The lack of a correctly charged mt-tRNA
would be predicted to impair all intra-mitochondrial
translation irrespective of which of mt-tRNA was in
short supply. However, recessively-inherited defects
in different aminoacyl mt-tRNA synthetases lead to
very different clinical phenotypes exhibiting marked
tissue specificity [29]. Similarly, different mt-tRNA
mutations would be predicted to affect overall intra-
mitochondrial translation but the degree to which each
gene product is synthesised cannot be so easily cor-
related with either the particular mutant mt-tRNA or
the relevant mt-aaRS. There are clearly other fac-
tors that play a part in modifying the severity of
the defects and further research is required to dissect
what these are and how they contribute to the clinical
phenotype.
Defective C12orf65-induced RC deficiency may be
responsible for a retrograde signal that causes the
increase in mitochondrial RNA seen in all patient
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Fig. 4. Gene expression analyses of OXPHOS components and related proteins. A. Intramitochondrial protein synthesis was measured in cell
lysates by incorporation of 35S-methionine and cysteine into fibroblasts derived from patient (P) or control (C). The relative positions of the
mt-proteins are indicated. Protein loading was confirmed by Coomassie blue (CBB) staining of the gel. B. Northern blot analysis was performed
on patient and control RNA (4g) to quantify the steady state levels of the RNA species indicated. The cytosolic 18 S rRNA was used as a
loading control. C. Similar analyses were performed on human kidney cells (HEK293) following 6 days siRNA mediated depletion of C12orf65
(lanes 1–3), or a non-targetting control siRNA (lanes 4–6) reflecting 3 experimental repeats. The cytosolic 18 S rRNA was used a loading control.
Westerns of patient and control mitochondrial lysates (12.5g) were separated by 12% SDS:PAGE to detect levels of mitoribosomal proteins
(D), respiratory chain proteins (E) or mitochondrial proteases (G) using porin as a loading control. F. Assembly and integrity of the OXPHOS
complexes was determined by blue native 4.5–16% gradient PAGE of mitochondrial lysates (25g) from patient and control. After transfer,
Western blot analysis was used to visualize all OXPHOS complexes with subunit specific antibodies as follows: complex I (NDUFA9), complex
III (Core 2) and complex II (SDHA), complex IV (COX4) and complex V (-subunit).
samples where mt-RNA levels were analysed (ibid
and [8]), and in cell lines following siRNA mediated
depletion of C12orf65. This may potentially reflect
a compensatory response directed at overcoming the
OXPHOS defect, however the defective C12orf65 pre-
vents any subsequent increase in protein synthesis.
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The cellular ATP requirements in this patient were
partially sustained by glycolysis, however under con-
ditions of higher energy demands the consequences of
the C12orf65 defect manifested as respiratory failure
with defective OXPHOS.
Of the identified C12orf65 mutations this individ-
ual harbours a previously reported frameshift mutation
that eliminates the GGQ domain and prematurely trun-
cates the protein ten amino acids beyond this domain,
generating one of the shortest reported C12orf65 pro-
teins (Fig. 2B, [13]). In distinction to the published
clinical reports of C12orf65 mutations, which are con-
sistent with the shortest proteins correlating with the
more severe symptoms (summarised in [13]), this indi-
vidual only presented in his fifth decade of life with
a milder and more restricted panoply of symptoms.
Mitochondrial disease was until recently classified as
a rare disorder [30, 31]. However, advances in our
understanding of the genetics, biochemistry, and clin-
ical presentations of these conditions have resulted in
increasingly effective diagnoses. This improved recog-
nition of mitochondrial disease is confirmed in a recent
study indicating an estimated prevalence of 1:4300
making these some of the most common inherited neu-
romuscular disorders [5].
In summary, we demonstrate for the first time, an
example where the severity of the clinical phenotype is
independent of the position of the truncating mutation
in the C12orf65 gene. Hence, cases such as the one
presented here, reinforce the complexity of the clinical
presentations of mitochondrial disease, where variable
combinations of symptoms, with different degrees of
severity, can manifest at any age.
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